Zobrazeno 1 - 10
of 73
pro vyhledávání: '"J S, Leeder"'
Autor:
Erin C. Boone, Robin E. Pearce, Jean C. Dinh, Vincent S. Staggs, J. S. Leeder, Roger Gaedigk, Andrea Gaedigk, Wendy Y. Wang
Publikováno v:
Clin Pharmacol Ther
rs5758550 has been associated with enhanced transcription and suggested to be a useful marker of CYP2D6 activity. As there are limited and inconsistent data regarding the utility of this distant "enhancer" single nucleotide polymorphism (SNP), our go
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b52b5bacab0e54c88f24260e76524e65
https://doi.org/10.1002/cpt.2469
https://doi.org/10.1002/cpt.2469
Autor:
Andrea Gaedigk, Lazara K M Jaime, Joseph S Bertino, Jr, Anick Bérard, Victoria Pratt, L D Bradford, J S Leeder
Publikováno v:
Frontiers in Pharmacology, Vol 1 (2010)
Polymorphic expression of CYP2D6 contributes to the wide range of activity observed for this clinically important drug metabolizing enzyme. In this report we describe novel CYP2D7/2D6 hybrid genes encoding non-functional and functional CYP2D6 protein
Externí odkaz:
https://doaj.org/article/4a67fa3c84df4e1fa65eae9fc2006954
Autor:
Roger Gaedigk, J. S. Leeder, Jashvant D. Unadkat, Bhagwat Prasad, L. Salphati, L. Gan, Guangqing Xiao, Cornelis E. C. A. Hop, Marc Vrana, Andrea Gaedigk, Raymond Evers, Xiaoyan Chu
Publikováno v:
Clinical Pharmacology & Therapeutics. 100:362-370
Protein expression of major hepatic uptake and efflux drug transporters in human pediatric (n = 69) and adult (n = 41) livers was quantified by liquid chromatography / tandem mass spectroscopy (LC-MS/MS). Transporter protein expression of OCT1, OATP1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6543b9cb7e77282065a1e522fa162e18
https://doi.org/10.1002/cpt.409
https://doi.org/10.1002/cpt.409
Autor:
V, Shakhnovich, S, Abdel-Rahman, C A, Friesen, J, Weigel, R E, Pearce, A, Gaedigk, J S, Leeder, G L, Kearns
Publikováno v:
Pediatric obesity. 14(1)
Children with obesity are more likely to suffer gastroesophageal reflux disease, requiring acid-suppression therapy with proton pump inhibitors (PPIs) and no guidelines regarding dosing.To prospectively evaluate lean-body-weight-based (LBW) dosing of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a0cd3a58757c6b02ade2482af05e8912
https://pubmed.ncbi.nlm.nih.gov/30257076
https://pubmed.ncbi.nlm.nih.gov/30257076
Autor:
Jeffrey R. Bishop, Stuart A. Scott, SG Leckband, Rebecca L. Graham, Julia C. Stingl, J. S. Leeder, DL Chiulli, Andrea Gaedigk, Daniel J. Müller, Todd C. Skaar, Kelly E. Caudle, Katrin Sangkuhl, JK Hicks, Yuan Ji, Adrián LLerena, Teri E. Klein
Publikováno v:
Clinical Pharmacology & Therapeutics. 98:127-134
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e34e9d2078f401c203667bb73759b968
https://doi.org/10.1002/cpt.147
https://doi.org/10.1002/cpt.147
Autor:
Iain MacPhee, Charles M. Stein, J. S. Leeder, Wolfgang Sadee, Alexander A. Vinks, Kenneth E. Thummel, Danxin Wang, Josh F. Peterson, Kelly E. Caudle, Yijing He, Jesse J. Swen, Brian S. Decker, Julia M. Barbarino, Kelly A. Birdwell, Ron H.N. van Schaik, Teri E. Klein
Publikováno v:
Clinical Pharmacology & Therapeutics, 98(1), 19-24. Wiley-Blackwell
Clinical Pharmacology and Therapeutics, 98(1), 19-24
Clinical Pharmacology and Therapeutics, 98(1), 19-24
Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose-adjusted trough concentration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9a310a81ce0d065dad7312eff286247
https://doi.org/10.1002/cpt.113
https://doi.org/10.1002/cpt.113
Autor:
SN de Wildt, Lawrence J. Lesko, J Boiani, J. S. Leeder, Niloufar Marsousi, Amin Rostami-Hodjegan, Alexander A. Vinks, Athena F. Zuppa, Adam S. Darwich, Kayode Ogungbenro, Michael Neely, Leon Aarons, Paolo Vicini, Youssef Daali, TN Johnson, C. A. J. Knibbe, Jeannine S. McCune, J. R. Powell, James M. Cook, J-L Reny, D Fairman
Publikováno v:
Clinical Pharmacology & Therapeutics, 101(5), 646-656. Wiley-Blackwell
Clinical Pharmacology and Therapeutics, 101, 5, pp. 646-656
Clinical Pharmacology and Therapeutics, 101, 646-656
Clinical Pharmacology and Therapeutics, Vol. 101, No 5 (2017) pp. 646-656
Darwich, A, Ogungbenro, K, Vinks, A A, Powell, J R, Reny, J-L, Marsousi, N, Daali, Y, Fairman, D, Cook, J, Lesko, L J, McCune, J S, Knibbe, C A J, de Wildt, S N, Leeder, J S, Neely, M N, Zuppa, A F, Vicini, P, Aarons, L, Johnson, T N, Boiani, J & Rostami-Hodjegan, A 2017, ' Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future ', Clinical Pharmacology & Therapeutics . https://doi.org/10.1002/cpt.659
Clinical Pharmacology and Therapeutics, 101, 5, pp. 646-656
Clinical Pharmacology and Therapeutics, 101, 646-656
Clinical Pharmacology and Therapeutics, Vol. 101, No 5 (2017) pp. 646-656
Darwich, A, Ogungbenro, K, Vinks, A A, Powell, J R, Reny, J-L, Marsousi, N, Daali, Y, Fairman, D, Cook, J, Lesko, L J, McCune, J S, Knibbe, C A J, de Wildt, S N, Leeder, J S, Neely, M N, Zuppa, A F, Vicini, P, Aarons, L, Johnson, T N, Boiani, J & Rostami-Hodjegan, A 2017, ' Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future ', Clinical Pharmacology & Therapeutics . https://doi.org/10.1002/cpt.659
Item does not contain fulltext Patient groups prone to polypharmacy and special subpopulations are susceptible to suboptimal treatment. Refined dosing in special populations is imperative to improve therapeutic response and/or lowering the risk of to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e093e184dffced0a86f5bdc936df3f2
https://pure.eur.nl/en/publications/5b047b0e-521f-4858-b9a2-9be56bee6d3b
https://pure.eur.nl/en/publications/5b047b0e-521f-4858-b9a2-9be56bee6d3b
Autor:
J. S. Leeder, Roger Gaedigk, Charlie Bi, Dick Tibboel, BD van Groen, Vincent S. Staggs, SN de Wildt
Publikováno v:
Archives of Disease in Childhood. 104:e60.1-e60
BackgroundAlternative mRNA transcripts occur in >90% of human genes and may be triggered by developmental signals. The hepatic transporter OATP1B1 (gene name SLCO1B1) traffics substrates across the hepatic membrane, and shows age-related changes in p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c3febd609b338b258657c060c87734b
https://doi.org/10.1136/archdischild-2019-esdppp.140
https://doi.org/10.1136/archdischild-2019-esdppp.140
Autor:
S. Islam, Pramann La, Rakesh K. Singh, J. S. Leeder, Shui Qing Ye, Mara L. Becker, Marcia A. Chan, Nicole M. Gigliotti, Ryan S. Funk, Daniel P. Heruth
Publikováno v:
Clinical and Translational Science
Variability in response to methotrexate (MTX) in the treatment of juvenile idiopathic arthritis (JIA) remains unpredictable and poorly understood. Based on previous studies implicating an interaction between nicotinamide phosphoribosyltransferase (NA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::751659a4fe237dd5fc3ff146253acbfc
https://pubmed.ncbi.nlm.nih.gov/27166432
https://pubmed.ncbi.nlm.nih.gov/27166432
Autor:
Andrea Gaedigk, J. S. Leeder, Susan M. Abdel-Rahman, Jacob T. Brown, L van Haandel, Yvonne S. Lin
The effect of CYP2D6 genotype on the dose-exposure relationship for atomoxetine has not been well characterized in children. Children 6-17 years of age diagnosed with attention-deficit hyperactivity disorder (ADHD) were stratified by CYP2D6 genotype
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::497c3549fd8cfdc8515c8b01b6650407
https://europepmc.org/articles/PMC4862932/
https://europepmc.org/articles/PMC4862932/